benefits of microdosing semaglutide There isn't enough data to confirm that GLP-1s can help you live longer, says UNC Hospitals clinical pharmacist practitioner Anne Komé. But it could help clinicians optimize therapy for patients who We are now offering micro-dosing!
Description
More recently, sodium-glucose cotransporter type 2 inhibitors have demonstrated to offer cardiovascular and renal protection, but the residual risk remains high and their antihyperglycemic efficacy is limited in moderate-severe CKD
GLP-1 receptor agonists (Wegovy, Saxenda, and soon Zepbound/Mounjaro for obesity) are now covered by many commercial insurers, though usually with prior authorization requirements: Medicare is about to change the game entirely
Having reviewed the benefits and risks, lets discuss who may be a suitable candidate for these medications
Who is a good candidate for Retatrutide or Ozempic
